TTY Biopharm Company Limited and 2-BBB Medicines BV set up the Taiwan-based joint venture company EnhanX Biopharma Inc. for the clinical and commercial development of the 2B3-201 product, now called ENX-201, specifically designed to enhance the treatment of neuro-inflammation, with an initial focus on treating patients with acute multiple sclerosis (MS) relapses.
TTY Biopharm Company Limited
was established in 1960. For more than fifty years, TTY Biopharm has transformed from a production and sales oriented traditional generic drug pharmaceutical factory into development and marketing of branded generic drugs. With unending self-renovation and transformation, we utilize the experience, technology, and relationship network accumulated over the decades to seek improvement. Today, we redefine ourselves as a biotech company focusing on developing special formulations and new drugs. We hope to finally achieve our enterprise vision of “raising the quality of life for mankind through science and technology, and improving the status of Chinese people in the life industry worldwide.”
2-BBB Medicines BV
is created to develop medicines for the treatment of devastating brain diseases. We believe that we can transform the lives of those affected faster and more successful by combining known disease targets and compounds with established drug delivery systems united with safe targeting technology. This has led to two programs in clinical development: 2B3-101 for brain cancer and 2B3-201 for neuro-inflammatory diseases. 2-BBB is based in the Netherlands on the Leiden Bio Science Park, and its subsidiary to-BBB Taiwan Ltd. is based in Taipei, Taiwan.